At a glance
ClinicalIndex Comparison RecordN/ACompleted· 196 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-term Follow-up of a Multicentre, Randomized, Double-blind, Placebo-controlled Trial (AN004T) Assessing the Efficacy and Tolerability of 2 Dosing Regimens of AllerT in Adult Subjects Allergic to Birch Pollen
In Brief
An observational study for Birch Pollen Allergy. Completed, enrolled 196 participants across 22 sites in 7 countries.
Detailed Summary
Study aiming to evaluate the efficacy of a 2-month pre-seasonal treatment with an AllerT 50 µg or 100 µg maintenance dose administered in previous study AN004T in reducing symptoms of allergic rhinoconjunctivitis during the 2nd following birch pollen season.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBirch Pollen Allergy
CountriesDenmark, France, Latvia, Lithuania, Poland, Sweden, Switzerland
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
First PostedMay 2014
Primary CompletionJul 2014
TodayJul 2026
First PostedMay 21, 2014
Enrollment StartFeb 1, 2014
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.1 years ago